Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin reuptake inhibition. Atypical antipsychotics, such as olanzapine, used in the augmentation of antidepressants causes not only a better response to treatment, but also increased number of remissions. The aim of our work was to evaluate the efficacy of vortioxetine monotherapy compared to the combined treatment vortioxetine and olanzapine in adult patients with depression during the acute phase of treatment lasting 6 weeks. Depressive symptomatology was assessed by the MADRS scale, anxiety symptoms were assessed by the HAM-A scale and global clinical impression were evaluated by the CGI-S scale. The number of patients in full-analysis set was 28. The results showed statistically significant improvement in CGI-S for both groups. Patients with vortioxetine monotherapy showed significant improvement in MADRS total score from the third week of treatment (p = 0.009) compared to patients with combined therapy that showed significant improvement since the end of first week of treatment (p = 0.036). Both groups showed significant improvement in HAM-A total score from the second week of treatment. Our results show the possibility of olanzapine in the augmentation strategy in treatment of major depressive disorder in adult patients.
If the inline PDF is not rendering correctly, you can download the PDF file here.
 Alvarez E Perez V Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297–1307.
 Farsky I Smetanka A Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441.
 Nemeroff CB. Prevalence and management of treatment resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25.
 Serreti A Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266.
 Jarema M Dudek D Czernikiewicz A. Cognitive dysfunctions in depression – underestimated symptom or a new dimension? Psychiatr. Pol. 2014;48(6):1105–1116.
 Pecenak J Korinkova V et al. Psychofarmakologia. 2016. Bratislava: Wolters Kluwer. ISBN 978-80-8168-542-2.
 Bobo V Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy safety and study design issues. Neuropsychiatric Disease and Treatment. 2009;5:369–383.
 Raskin A Schulterbrandt JG Reatig N McKeon JJ. Differential response to chlorpromazine imipramine and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry. 1970;23:164–173.
 Papakostas GI Shelton RC Shmith J Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68:826–831.
 Kessler RC Sampson NA Berglund P et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol. Psychiatr. Sci. 2015;24:210–226.
 Pae CU Wang SM Han C Lee SJ Patkar AA Masand PS Serretti A. Vortioxetine a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J. Psychiatr. Res. 2015;64: 88–98.